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Abstract
Receptors for the angiogenic factor VEGF are expressed by tumor cancer cells including melanoma, although their
functionality remains unclear. Paired human melanoma cell lines WM115 and WM239 were used to investigate
differences in expression and functionality of VEGF and VEGFR2 in vitro and in vivo with the anti-VEGF antibody
bevacizumab. Both WM115 and WM239 cells expressed VEGF and VEGFR2, the levels of which were modulated
by hypoxia. Detection of native and phosphorylated VEGFR2 in subcellular fractions under serum-free conditions
showed the presence of a functional autocrine as well as intracrine VEGF/VEGFR2 signaling loops. Interestingly,
treatment of WM115 and WM239 cells with increasing doses of bevacizumab (0-300 μg/ml) in vitro did not show
any significant inhibition of VEGFR2 phosphorylation. Small-molecule tyrosine kinase inhibitor, sunitinib, caused
an inhibition of VEGFR2 phosphorylation in WM239 but not in WM115 cells. An increase in cell proliferation
was observed in WM115 cells treated with bevacizumab, whereas sunitinib inhibited proliferation. When xeno-
grafted to immune-deficient mice, we found bevacizumab to be an effective antiangiogenic but not antitumori-
genic agent for both cell lines. Because bevacizumab is unable to neutralize murine VEGF, this supports a
paracrine angiogenic response. We propose that the failure of bevacizumab to generate an antitumorigenic effect
may be related to its generation of enhanced autocrine/intracrine signaling in the cancer cells themselves. Collec-
tively, these results suggest that, for cancers with intracrine VEGF/VEGFR2 signaling loops, small-molecule inhibi-
tors of VEGFR2 may be more effective than neutralizing antibodies at disease control.
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Introduction
Vascular endothelial growth factor (VEGF-A) is an important regulator
of both normal and pathologic angiogenesis [1,2]. To date, bevacizumab
(Avastin), an anti-VEGF antibody, alone or in combination with chemo-
therapy, has shown clinical activity in colorectal [3,4], breast [5,6],
ovarian [7], non–small cell lung [8], metastatic renal cell carcinoma
[9], and glioblastoma multiforme [10], validating VEGF pathway inhib-
itors as an important treatment modality in cancer therapy [11]. Phase 2
studies of metastatic malignant melanoma report that up to 25% of
patients with advanced cancer may show prolonged disease stabiliza-
tion [12], and most studies demonstrate that bevacizumab in combina-
tion with chemotherapy or immune therapy shows moderate activity
[13,14]. Sunitinib or SU11248 (Sutent; Pfizer) is an oral multitargeted
tyrosine kinase inhibitor that inhibits phosphorylation of a variety of
tyrosine kinases such as VEGFR1-3, and platelet-derived growth factor
receptor β [15]. Sunitinib is effective as an antiangiogenic and antitumor
reagent in both preclinical mouse models [16] and human clinical trials
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of non–small lung cancer [17], breast cancer [18], metastatic renal cancer
[19], and other tumor types.
Within solid tumors, VEGF is mainly produced by cancer cells,
and it binds in paracrine fashion to endothelial VEGFR1 (Flt-1),
VEGFR2 (KDR, human/Flk-1, mouse), and neuropilin receptors
(NRP1 and NRP2) [20]. VEGFR2 is responsible for most down-
stream angiogenic effects of VEGF including changes in vascular per-
meability, endothelial proliferation, invasion, migration, and survival
[21]. Binding of VEGF to VEGFR2 also activates downstream sur-
vival and migration pathways involving PI3-kinase/Akt and focal
adhesion kinase, respectively [22].
In addition to these paracrine functions, VEGF may also be in-
volved in autocrine stimulation of tumor growth, binding specifically
to VEGFRs present on cancer cells themselves [23–26]. The pres-
ence of VEGF receptors on human melanoma cells suggests the pos-
sibility of an autocrine VEGF/VEGFR signaling loop in this disease
[27–29]. Overexpression of VEGF165 in a melanoma cell line that
expresses VEGFR2 favors cell growth and survival through MAPK
and PI3K signaling pathways [27]. Some VEGF receptors may not
be expressed on the surface of the cancer cells but instead remain in-
tracellular, promoting survival through a VEGF/VEGFR “intracrine”
mechanism [27,30,31].
Here we used the paired human melanoma cell lines (WM115 and
WM239) [32] to investigate differences in expression of VEGF and
VEGFR2. We identified autocrine as well as intracrine VEGF/VEGFR2
signaling in both primary (WM115) and metastatic (WM239) mela-
noma cell lines and investigated the signaling of these pathways and their
possible impact on tumor responses to VEGF targeted therapy using
xenografted cells.
Materials and Methods
Cell Lines and Culture Conditions
The following cell lines were purchased from American Type Cul-
ture Collection (Manassas, VA) and used in experiments — WM115
(primarymelanoma [32]),WM239 (metastatic melanoma, isolated from
a secondary lesion from the same patient [32]), bEnd3 (a mouse brain-
derived polyoma middle T antigen-transformed endothelial cell line),
and 293T (human fetal kidney) [33]. Primary bovine aortic endothelial
cells (BAECs) were isolated from aorta of adult cattle and characterized
as previously reported [34]. Human umbilical vein endothelial cells
(HUVECs) were purchased from Lonza (Allendale, NJ). Cells were
routinely cultured in Dulbecco modified Eagle medium (DMEM;
Sigma-Aldrich, Mississauga, Canada) supplemented with 10% fetal
bovine serum (FBS; Life Technologies, Burlington, Canada), sodium
pyruvate (Sigma-Aldrich), and gentamicin (Life Technologies) at 37°C
in 5% CO2 and 95% air.
Reverse Transcription–Polymerase Chain Reaction
Confluent cultures ofWM115 andWM239, 293T, and bENd3 cells
were lysed using TriPure (Roche,Mississauga, Canada) and 5 μg of total
RNA was used for complementary DNA (cDNA) synthesis with the
Turbo DNAse kit (Amgen, Streetsville, Canada). Reverse transcription–
polymerase chain reaction was performed for 30 cycles of 95°C
for 1minute, 60°C for 1minute, and 72°C for 2minutes. The polymerase
chain reaction products were separated using 2% agarose gel electro-
phoresis. Primer sequences for human and mouse VEGFR2 were
5′-CCAAGAACTCCATGCCCTTA-3′ for the antisense and 5′-ATCC-
CTGTGGATCTGAAACG-3′ for the sense strand. Negative controls
were performed on samples containing no reverse transcriptase enzyme
and using reaction buffer without cDNA template.
Establishment of Tumor Xenografts
All procedures described below were done according to the guide-
lines and recommendations of the Canadian Council of Animal Care
and approved by the University of Guelph Local Animal Care Com-
mittee. Tumor xenografts were established in 8-week-old female
athymic nude mice (Charles River, Sherbrooke, Canada) by injecting
2 × 106 of WM115 or WM239 melanoma cells in 100 μl of 0.1%
bovine serum albumin (BSA) subcutaneously into the right flank.
Tumor growth was measured twice weekly using calipers, and tumor
size was calculated using the equation: volume = length × width2 × 0.5.
Once tumors reached approximately 100 mm3 in size, mice were
randomly allocated into control or treatment group, eight per group.
Groups were treated for 14 (WM115 xenografts) or 21 (WM239 xeno-
grafts) days with bevacizumab as Avastin intraperitoneally, 5 mg/kg
twice weekly; mice in control groups received 100 μl of phosphate-
buffered saline (PBS) twice weekly. Mice were killed by CO2 asphyxia-
tion followed by cervical dislocation. Tumors were removed from the
surrounding tissue, embedded in OCT cryomatrix and snap frozen in
liquid nitrogen or snap frozen in liquid nitrogen for future protein and
RNA isolation, and stored at −80°C.
Western Blot Analysis
Cultured cell lines (WM115, WM239, and BAECs) were seeded at
the appropriate densities and allowed to attach overnight in DMEM
(Sigma-Aldrich) plus 10% FBS (Life Technologies). To be certain that
phosphorylation of VEGFR2 is achieved through production of VEGF
ligand by melanoma cells themselves and not by VEGF supplied in
added serum, cells were thoroughly washed in PBS and serum-starved
for 48 hours. Melanoma cells were treated with control human IgG
antibody or 150 μg/ml of bevacizumab (Avastin) for 15 or 30 minutes
before lysis. Cells were also incubated in a modular hypoxic chamber
(Billups-Rothenberg, Del Mar, CA) under less than 0.01% oxygen for
24 and 48 hours and then lysed in protein lysis buffer containingNa3VO4
and phosphatase inhibitor cocktail 2, according to the manufacturer’s
instructions (Sigma-Aldrich). Cells were treated with 1 mM pervanadate
for 30 minutes before lysis, and nuclear and cytosolic fractions were col-
lected using the Nuclear and Cytosolic Fractionation kit (LabVision,
Kalamazoo,MI). Frozen tumor pieces fromWM115 andWM239 xeno-
grafts were disrupted in freshly prepared lysis buffer (Cell Signaling,
Danvers, MA), and total protein lysates were electrophoretically resolved
on 7.5% polyacrylamide gels and transferred to a polyvinylidene fluoride
membrane (Roche). Membranes were blocked in 5% milk or 5% BSA
(Jackson ImmunoResearch, West Grove, PA) in TBS/Triton followed
by overnight incubation at 4°C in primary antibodies diluted in 5%milk
or 5% BSA in TBS/Triton. Primary antibodies used were rabbit anti-
VEGFR2, rabbit anti–phospho-VEGFR2 Tyr951, rabbit anti–phospho-
VEGFR2 Tyr1175 (all 1:1000 dilution; all Cell Signaling Technology),
mouse anti–α-tubulin (1:400,000; Sigma-Aldrich), and rabbit anti-lamin
(1:1000; Cell Signaling Technology). Membranes were washed and
treated with appropriate POD-conjugated secondary antibody (anti-
rabbit POD at 1:10,000 and anti-mouse POD at 1:40,000; Sigma-
Aldrich) and immunocomplexes visualized using a chemiluminescence
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detection kit (Roche), exposed to an x-ray film and quantified on a
FluorChem 9900 gel documentation imaging system (Alpha Innotech,
San Leandro, CA). Protein loading was normalized using α-tubulin
bands from protein lysates.
Nuclear/Cytosolic Fractions
Cultured cell lines (WM115, WM239, and BAECs) were seeded at
the appropriate densities, allowed to attach overnight in DMEM
(Sigma-Aldrich) plus 10% FBS (Life Technologies), and then thor-
oughly washed in PBS and serum-starved for 48 hours. Cells were
rinsed once with PBS and fresh serum-free medium containing 1 mM
pervanadate was added to cells 30 minutes before lysis. Melanoma cells
were treated with 0 or 50 μg/ml bevacizumab as Avastin, with and
without 5 ng/ml human recombinant VEGF (Life Technologies) for
15 or 30 minutes. Nuclear and cytosolic fractions were collected using
the Nuclear and Cytosolic Fractionation kit (LabVision).
Dose Response
Cultured cell lines (WM115, WM239, and BAECs) were seeded
at the appropriate densities, allowed to attach overnight in DMEM
(Sigma-Aldrich) plus 10% FBS (Life Technologies), and then thor-
oughly washed in PBS and serum-starved for 48 hours. Cells were
rinsed once with PBS and fresh serum-free medium containing 1 mM
pervanadate was added to cells 30 minutes before lysis. Melanoma cells
were treated with 0, 50, 150, and 300 μg/ml bevacizumab as Avastin or
0, 10, 100, or 300 nM sunitinib (Sigma-Aldrich), with and without 10
and 5 ng/ml human recombinant VEGF (Life Technologies), respec-
tively, for 15 minutes. Cells were lysed in protein lysis buffer containing
Na3VO4 and phosphatase inhibitor cocktail 2, according to the manu-
facturer’s instructions (Sigma-Aldrich). Protein lysates were electro-
phoretically resolved on 7.5% polyacrylamide gels and transferred to a
polyvinylidene fluoride membrane (Roche). Membranes were blocked
in 5% milk or 5% BSA (Santa Cruz Biotechnologies, Santa Cruz, CA)
followed by overnight incubation at 40°C in primary antibodies diluted
in 5% milk or 5% BSA in TBS/Triton. Primary antibodies used were
rabbit anti-VEGFR2, rabbit anti–phospho-VEGFR2 Tyr951, rabbit
anti–phospho-VEGFR2 Tyr1175, (all 1:2000 dilution; all Cell Signal-
ing Technology), mouse anti–α-tubulin (1:400,000; Sigma-Aldrich),
and rabbit anti-lamin (1:1000, Cell Signaling Technology).Membranes
were washed and treated with appropriate POD-conjugated secondary
antibody (anti-rabbit POD at 1:20,000 and anti-mouse POD at
1:20,000; Sigma-Aldrich), and immunocomplexes were visualized using
Luminata Western HRP Chemiluminescence Substrate (Millipore),
exposed to an x-ray film, and quantified on a FluorChem 9900 gel
documentation imaging system (Alpha Immunotech). Protein loading
was normalized using α-tubulin bands from protein lysates.
Crystal Violet Assay
Cultured cell lines (WM115 and WM239) were seeded at the
appropriate densities and allowed to attach overnight in DMEM
(Sigma-Aldrich) plus 10% FBS (Life Technologies). Cells were treated
with 0, 10, 100, or 300 nM sunitinib or 0, 50, 150, or 300 μg/ml
bevacizumab inDMEMplus 1%FBS for 6 days, replacing themedium
every 2 to 3 days. Cells were fixed and stained in 1%Crystal Violet, 20%
methanol for 20minutes at room temperature and rinsedmultiple times
with distilled H2O. Once completely dried, stained cells were dissolved
in 10% acetic acid for 20 to 30 minutes at room temperature and
absorbance at 570 nm was determined.
Measurement of Human VEGF Protein Levels
A human VEGF ELISA kit (R&D Systems, Inc, Minneapolis,
MN) was used to quantify VEGF in serum-free conditioned medium
from WM115 and WM239 cells. Serum-starved cells were treated
with control human IgG antibody, 50 or 150 μg/ml of bevacizumab
as Avastin. Conditioned medium was collected 6 and 24 hours later
and used immediately or stored at 4°C until VEGF quantification.
Measurement of VEGF protein levels was performed on ELX800
(BioTek, Winooski, VT) plate reader. Adherent cells were tryp-
sinized and counted using a hemocytometer for normalization pur-
poses. VEGF ELISA was also used to quantify levels in lysed tumor
xenografts from each of the treatment groups (control and bevacizumab)
and normalized to total protein.
Immunofluorescence for Phosphorylated and Native VEGFR2
Receptor in Cultured Cells
WM115 and WM239 cells were cultured on sterile glass cover-
slips for 48 hours and exposed to 10 ng/ml VEGF or vehicle for
1 hour time. Coverslips were then fixed with 4% paraformaldehyde
(USB Corporation, Cleveland, OH) at room temperature and per-
meabilized in 0.3% Triton X-100, and nonspecific binding was
blocked using protein block (Dako, Burlington, Canada) for 30 min-
utes. Cells were incubated in rabbit anti-VEGFR2 antibody (Cell
Signaling Technology) diluted 1:50 in PBS with 0.3% Triton X-100
overnight at 4°C or rabbit phospho-VEGFR2 Tyr951 (Cell Signaling
Technology) at 1:400, followed by fluorescently tagged anti-rabbit
Cy3 secondary antibody (1:200; Jackson ImmunoResearch) for 30 min-
utes. Slides were counterstained with DAPI (Dako) and mounted using
fluorescent mounting medium (Dako). Images were captured with a
20× objective using QCapture software calibrated to a Leica DMLB
microscope (Leica, Wetzlar, Germany) fitted with a QImaging QICAM
fast1394 digital camera (QImaging, Surrey, Canada). Images were
merged using Adobe Photoshop 7.0 (Adobe).
Blood Vessel Density Quantification
To determine blood vessel density, two blocks from each tumor
xenograft were assessed. Cryosections, 8 μm thick, were fixed in
50:50 acetone-methanol mix for 10 minutes at −20°C and air-dried.
Sections were rehydrated in PBS, and nonspecific binding was
blocked using Dako protein-free block (Dako) for 1 hour followed
by 1 hour in rat anti-CD31 antibody (1:50; Hyclone, Logan, UT) and
then 30 minutes in donkey anti-rat FITC (1:200; Jackson Immuno-
Research). Slides were counterstained with DAPI and mounted as
described. Sections were examined by epifluorescence microscopy,
and images were captured with a 20× objective in a blinded fashion.
Optimas 6.2 image analysis software program (MediaCybernetics,
San Diego, CA) was used to determine the total number of blood
vessels for each field to obtain the blood vessel density.
Statistical Analysis
Calculation of preliminary summary statistics such as mean, SD,
and SE as well as graphing all the data was completed using Microsoft
Excel (Microsoft Corp, Mississauga, Canada). On all samples, Grubbs’
test, also called the ESD method (extreme studentized deviate), was
used to determine significant outliers. Once outliers, if any, were iden-
tified and omitted from the analysis, analysis of variance was perform to
determine the significance within and between groups (P < .05). Least
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significant difference (Tukey) test was used to determine whether there
were significant differences between groups. Data were presented as
mean, SE, and range.
Results
VEGF and VEGFR2 Expression in Melanoma Cell Lines
Using ELISA, we detected the expression of VEGF in both WM115
and WM239 melanoma cell lines and observed an approximately
10-fold increase in the production of VEGF by metastatic (WM239)
compared with primary (WM115) melanoma cells (Figure 1, A and
B). The humanized anti-VEGF antibody bevacizumab was able to sig-
nificantly neutralize available VEGF in the conditioned medium of
WM115 cells by 24 hours (at 150 μg/ml, P < .05; Figure 1A) and of
WM239 cells after 6 and 24 hours (at 50 and 150 μg/ml, P < .05;
Figure 1B). VEGFR2 mRNA was detected in both primary and meta-
static melanoma cell lines (Figure 1C). Western blot analysis confirmed
the expression of VEGFR2 protein in both cell lines; WM115 cells
express approximately 40% to 50% less VEGFR2 protein than BAECs,
whereas WM239 melanoma cells express approximately 80% to 90%
less VEGFR2 protein than BAECs (P < .05; Figure 1D). Also, there
was significantly higher VEGFR2 expression in WM115 primary than
in WM239 metastatic melanoma cells (P < .05; Figure 1D).
Functional Autocrine and Intracrine VEGF/VEGFR2
Signaling Loops
Once the presence and the relative amounts of the VEGF ligand and
its receptor VEGFR2 were determined, we investigated the existence
Figure 1. Expression of VEGF and VEGFR2 in melanoma cell lines in vitro. (A) Levels of VEGF ligand were measured in serum-free CM of
primary (WM115) and (B) metastatic melanoma cell line (WM239) which were treated with bevacizumab (50 and 150 μg/ml) or control IgG.
Graphs show that metastatic melanoma cells (WM239) have significantly upregulated VEGF expression compared with primary melanoma
cells (WM115). In addition, significant inhibition of VEGF was observed in WM115 and WM239 cell lines treated with bevacizumab (50
or 150 μg/ml) compared with controls (50 μg/ml: *P < .05; 150 μg/ml: †P < .05). n = 3. (C) Agarose gel stained with ethidium bromide
showing VEGFR2 cDNA amplicons in both primary (WM115) and metastatic (WM239) melanoma cell lines. Human fetal kidney (293T)
and mouse brain microvascular cells (bENd3) were used as negative and positive control, respectively. (D) A representative Western blot
of VEGFR2 protein expressed by BAECs (positive control), WM115, and WM239 cells. α-Tubulin was used for normalization purposes.
Densitometry of these blots shows significant differences in the expression of VEGFR2 in melanoma cell lines compared to each other
(†P < .05) as well as control (*P < .05). n = 3.
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Figure 2. Detection of phosphorylated VEGFR2 and native VEGFR2 receptor. (A) Immunofluorescent staining was performed on all three
cell lines tested, WM115, WM239, and HUVECs, with and without exogenously added VEGF for the presence of native VEGFR2 and phos-
phorylated VEGFR2 (at Tyr951 and Tyr1175). Images show the presence of native and phosphorylated VEGFR2 in cytoplasm and nucleus
(arrows) of WM115, WM239, and HUVEC cell lines. In addition, phosphorylation of VEGFR2 at Tyr951 is observed in both the cytoplasm
and nucleus, whereas the phosphorylation of VEGFR2 at Tyr1175 is observed mostly in cytoplasm. Negative controls (no primary antibody)
showed no detectable staining. Scale bar, 10 μm. (B) Expression of native VEGFR2 receptor detected in the nuclear, cytosolic, and total
protein lysate fractions in WM115 and WM239 cells was evaluated using Western blot analysis. α-Tubulin (cytosolic fractions) and lamin
(nuclear fractions) was used for normalization purposes. Blots show the presence of VEGFR2 protein in both nuclear and cytosolic fractions,
confirming immunofluorescent results.
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of a functional autocrine VEGF/VEGFR2 signaling loop in WM115
and WM239 cells. Immunofluorescent staining was used after an over-
night starvation of WM115, WM239, and HUVECs and revealed
the presence of phosphorylated (at Tyr951 and Tyr1175) and native
VEGFR2 in both plasma membrane and nucleus in both WM115
and WM239 cell lines, as well as in HUVECs, used as a control endo-
thelial cell line (Figure 2A). Whereas phosphorylation of VEGFR2
at Tyr951 is observed primarily in the nucleus of all three cell lines
examined, phosphorylated VEGFR2 at Tyr1175 was observed mostly
in the cytoplasm and the plasma membrane. Also, addition of exoge-
nous VEGF ligand did not change the expression or the localization
of native or phosphorylated VEGFR2 in any of the cell lines exam-
ined. The presence of phospho-VEGFR2 (Tyr951 and Tyr1175)
in samples obtained after extensive serum starvation suggests the exis-
tence of both an autocrine and an intracrine VEGF/VEGFR2 signal-
ing loop in both primary and metastatic melanoma cells. When total
cell lysates as well as separate cytosolic and nuclear fractions were
examined using Western blot analysis, VEGFR2 was observed in all
samples (Figure 2B).
Contrary to expectations, in general, the anti–VEGF-neutralizing
antibody bevacizumab failed to inhibit VEGFR2 phosphorylation in
both WM115 and WM239 cells (Figure 3, A-D), with few exceptions.
Figure 3. Effects of bevacizumab treatment on VEGFR2 phosphorylation in cytosolic and nuclear fractions of WM115 and WM239 mel-
anoma cells in vitro. Addition of 50 μg/ml of bevacizumab had no significant effect on phosphorylation of VEGFR2 receptor (at Tyr951
and Tyr1175) in cytosolic fractions 15 and 30 minutes after addition (+/−VEGF) (A), whereas it significantly inhibited VEGFR2 phosphor-
ylation at Tyr951 (both 15 and 30 minutes after addition, −VEGF) and Tyr1175 (15 minutes after addition, +VEGF) in nuclear fractions in
WM115 cells (B). (C) Similarly, addition of 50 μg/ml of bevacizumab to the medium of WM239 cells only had a significant inhibitory effect
on phosphorylation of VEGFR2 at Tyr1175 in cytosolic fractions after 15 minutes (−VEGF). (D) No significant change in phosphorylation
of VEGFR2 (Tyr 951/1175) was observed in nuclear fractions 15 and 30 minutes after bevacizumab addition (+/−VEGF). All images
shown are representative of three blots; densitometry results are shown in Table W1.
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Figure 4. Dose responses to bevacizumab and sunitinib on the phosphorylation of VEGFR2 in WM115 and WM239 cells. (A, B) Neither
WM115 nor WM239 cells show significant reduction in VEGFR2 phosphorylation to increasing bevacizumab concentrations (0-300 μg/ml).
(C, D) Increased dosing of sunitinib (0-300 nM) had no significant effect on phosphorylation of VEGFR2 (at Tyr951/1175) in WM115 cells.
On the contrary, significant inhibition of VEGFR2 phosphorylation in WM239 cells was observed at Tyr951 (+/−VEGF; *,§P < .05) and
at Tyr1175 (−VEGF) (§P < .05; n = 4). (E) A representative Western blot of results depicted in A to D showing protein changes after
bevacizumab (left) and sunitinib (right) treatment. (F) A representative Western blot shows dose-dependent (0-150 μg/ml) inhibition of
VEGFR2 phosphorylation (Tyr951/1175) using bevacizumab in HUVECs. α-Tubulin was used for normalization purposes.
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InWM115 cells, bevacizumab (at 50 μg/ml) inhibited phosphorylation
of VEGFR2 at Y951, 15 and 30 minutes after addition (no exoge-
nously VEGF added) and at Y1175 site after 15 minutes (with addi-
tion of VEGF)—as detected in nuclear fractions (P < .05; Figure 3B).
Cytosolic fractions of WM115 cells treated with bevacizumab did not
show inhibition of VEGFR2 phosphorylation regardless of exogenous
VEGF (Figure 3A). In WM239 cells, bevacizumab (at 50 μg/ml) caused
an inhibition of phosphorylated VEGFR2 at Y1175, 15 minutes after
addition—observed only in cytosolic fractions (P < .05; Figure 3C ).
There was no significant inhibition of VEGFR2 phosphorylation ob-
served in nuclear fractions (Figure 3D), and addition of exogenous VEGF
did not affect these results.
To see if an inhibition of VEGFR2 phosphorylation is dependent
on the dose of bevacizumab administered, total protein lysates were
collected from WM115 and WM239 cells treated with 0, 50, 150, and
300 μg/ml of bevacizumab (Figure 4, A, B, and E). No significant inhi-
bition of VEGFR2 phosphorylation was observed in either WM115 or
WM239 cells (+/−VEGF) at any of the concentrations of bevacizumab.
Next, cells were treated with VEGFR2 phosphorylation inhibitor
sunitinib at 0, 10, 100, and 300 nMwith an aim to observe dose response
(Figure 4, C -E). Although WM115 showed no significant inhibition
of phosphorylated VEGFR2 after sunitinib treatment, WM239 cells
showed a significant decrease (P < .05) in phosphorylated VEGFR2 at
Y951 (+/−VEGF) and at Y1175 (−VEGF) after sunitinib treatment.
To verify the activity of bevacizumab, we treated HUVECs with 0,
50, and 150 μg/ml bevacizumab and evaluated receptor phosphoryla-
tion. As expected, a dose-dependent reduction in phosphorylation was
observed in this cell type at both Y951 and Y1175 sites on VEGFR2
(Figure 4F ).
Sunitinib, but Not Bevacizumab, Decreases Cell Proliferation
of Melanoma Cells
Along with detection of phosphorylated VEGFR2 changes, pro-
liferation assays were performed to assess relative cell growth of
melanoma cells in response to an increased doses of bevacizumab
(0, 50, 150, and 300 μm/ml) as well sunitinib (0, 10, 100, and
300 nM; Figure 5). Sunitinib treatment caused significant reduc-
tion in cell proliferation compared with controls in WM239 but
not in WM115 cell line (P < .05; Figure 5A). Bevacizumab treatment
not only failed to inhibit cell proliferation in both cell lines but also
increased their growth at the highest dosage of 300 μg/ml (P < .05;
Figure 5B).
Bevacizumab Is Antiangiogenic in Primary and Metastatic
Melanoma Xenografts
To test the functionality of VEGF/VEGFR2 autocrine signaling loop
and evaluate the therapeutic properties of bevacizumab in melanoma,
Figure 5. Effect of VEGFR2 inhibition on melanoma cell growth.
(A) WM115 cells, but not WM239 cells, were susceptible to growth
inhibition by sunitinib (*P < .05 vs control; n = 3). (B) In contrast,
neither cell line was growth inhibited by bevacizumab, and WM115
cells showed significant growth enhancement at the highest dose
(*P < .05 vs control; n = 6).
Figure 6. Impact of bevacizumab on growth of melanoma xeno-
grafts. The tumor volume in WM115 (A) and WM239 (B) xeno-
grafts did not differ signif icantly between control and
bevacizumab-treated groups at any point during the treatment
(P ≥ .05). n = 8. (C) Quantification shows significant differences
(*P < .05) in average blood vessel density between control and
bevacizumab-treated groups for both cell lines.
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we used this agent to treat mice bearing WM115 and WM239 mela-
noma xenografts. There were no significant differences in average
tumor volume in bevacizumab-treated mice compared with control
for either primary melanoma (WM115) or metastatic melanoma
(WM239; Figure 6, A and B). For WM115, control tumors were
1.2-fold larger than treated at end point, and for WM239, control
tumors were 1.4-fold larger than treated at end point; these differences
were not significant (P > .05). However, immunofluorescence for the
pan-endothelial marker CD31 revealed significant differences (P < .05)
in blood vessel density between melanoma xenografts treated with
bevacizumab versus control (Figure 6C).
VEGFR2 expression was evaluated in tumor lysates, revealing
no differences. Although there was a trend toward reduced VEGFR2
levels in bevacizumab-treated tumors, this was not significant (P ≥
.05; Figure 7, A and B). Moreover, when we investigated the levels
of VEGF ligand in WM115 and WM239 xenografts treated with or
without bevacizumab, we observed that bevacizumab-treated WM239
tumors had significantly less VEGF (P < .05; Figure 7C) than control
xenografts. WM115 xenografts did not show this difference (P ≥ .05;
Figure 7C ).
Down-regulation of VEGFR2 in Severe Hypoxia
Western blot analysis of melanoma cell lysates revealed that severe
in vitro hypoxia (O2 < 0.01%) produced a significantly (P < .05) de-
creased expression of VEGFR2 receptor in WM115 and WM239
melanoma cells at both 24 and 48 hours. In fact, hypoxia almost
completely diminished WM239 expression of VEGFR2 (Figure 8,
A and B).
Discussion
Although endothelial signaling of VEGF ligand via VEGFR2 is well
characterized in tumor vasculature, VEGFR2 signaling on cancer
cells themselves is less understood, despite the fact that the expression
of VEGFR2 by different types of cancer cells has been well docu-
mented in the past decade [27,35–38]. However, the concomitant
expression of VEGF and VEGFR2 suggests modulation of biologic
effects, such as cell survival and cell migration, in an autocrine fash-
ion [24–26,29,37,39]. An autocrine VEGF/VEGFR2 signaling loop
in breast cancer has been associated with increased activation of p38
MAPK [23]. Some melanoma cells express VEGFR2, where it may
function as a mediator of the mitogenic effects of VEGF, but nor-
mal melanocytes completely lack the expression of either VEGF or
VEGFR2 [21,40].
We found a functional autocrine VEGF/VEGFR2 signaling loop in
human malignant melanoma cells and significantly lower VEGFR2
expression by cells derived from a metastatic lesion (WM239) com-
pared to those from a primary lesion (WM115) or to normal endo-
thelial cells. Aggressive melanoma tumor cells have been shown to
Figure 7. Expression of VEGFR2 in melanoma xenografts. (A) Rep-
resentative Western blots of lysed WM115 and WM239 xeno-
grafts with quantified VEGFR2 protein expression. α-Tubulin was
used for normalization purposes. (B) Densitometry shows no sig-
nificant differences (P ≥ .05) between control and bevacizumab-
treated groups in expression of VEGFR2 receptor. n = 4. (C) When
VEGF was quantified in lysed tumor xenografts using ELISA, sig-
nificant differences (*P < .05) were observed in the levels of VEGF
in bevacizumab-treated group compared with control for WM239
tumors but not WM115. n = 3.
Figure 8. Expression of VEGFR2 receptor under hypoxic conditions
in vitro. (A) Representative, composite blots showing the expression
of VEGFR2 receptor in primary (WM115) and metastatic (WM239)
melanoma cells when exposed in 24 and 48 hours of hypoxia.
α-Tubulin was used for normalization purposes. (B) Quantification of
expression demonstrates significant decrease in VEGFR2 levels
in WM115 melanoma cells when exposed to hypoxia for 24 and
48 hours. *P < .05. n = 3. VEGFR2 expression was undetectable in
WM239 cells exposed to hypoxia (densitometry not shown).
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“masquerade” as other cell types and express genes associated with
many other cellular phenotypes such as epithelial, pericyte, fibro-
blast, and hematopoietic cells [41,42]. Melanoma cells have also been
reported capable of “vascular mimicry”—expression of endothelium-
associated genes and formation of vascular networks similar to
formation of embryonic vascular networks [43,44]. In fact, melanomas
have been shown to relay on embryonic signaling pathways, such as
expression of the embryonic morphogen, Nodal, part of the TGF-β
superfamily. Nodal has been shown to interact with Notch4 pathway
in aggressive melanomas [45,46].
We found that cells derived from metastatic melanoma secreted
significantly more VEGF compared to cells derived from primary
melanoma (observed in both in vitro and in vivo experiments). This
is not surprising because the ability of melanomas to produce large
amounts of VEGF is one of their hallmarks [27,38,47], and the
hyperpermeability of the newly formed blood vessels caused by VEGF
plays an important role in melanoma metastasis [47]. Human mela-
noma cells, which simultaneously produce VEGF and express VEGFRs,
exhibit a higher spontaneous ability to invade the extracellular matrix
(ECM) than melanoma cells not expressing either ligand or recep-
tor [28]. This overproduction of VEGF may trigger VEGFR2 re-
ceptor down-regulation and degradation [48] therefore accounting
for the reduced VEGFR2 levels seen in WM239 cells compared to
WM115 cells.
In addition, our studies confirm that the anti-VEGF antibody,
bevacizumab, is effective in neutralizing virtually all VEGF secreted
by these melanoma cells [49]. Despite this, we found that treatment
of human melanoma cells with bevacizumab not only failed in most
instances to inhibit VEGFR2 phosphorylation in vitro but also actu-
ally produced increased cellular proliferation of melanoma cells. This
phenomenon has not been reported in the literature; in fact, other
studies show that bevacizumab inhibits VEGFR2 phosphorylation
in tumor vessels of breast cancer [50], lung cancer [51], and human
microvascular endothelial cells [52]. In support of this, we find that
bevacizumab worked in an “orthodox” fashion on HUVECs in our
hands. It is not clear why this reagent should show such differential
response between endothelial cells expressing VEGFR2 and cancer
cells expressing the same receptor. We speculate that bevacizumab
may have bound to the melanoma VEGFR2, perhaps in complex
with extensive soluble VEGF, leading to receptor clustering and
autoactivation. Alternatively, it is possible that internalized com-
plexes of VEGF and bevacizumab may continue to signal through
VEGFR2 Tyr951 through complexes in early endosomes in these
cells, as has recently been demonstrated in endothelial cells [53]. Fur-
ther studies are required to elucidate this pathway in melanoma cells.
Autocrine VEGF/VEGFR2 signaling in the melanoma cells pre-
sents an attractive second compartment for targeted anti-VEGF ther-
apy. However, when we treated our experimental melanoma tumors
with a bevacizumab dose regimen shown to be effective in other
human cancer xenografts [54], we did not get the expected antitumor
response. Although bevacizumab caused a decrease in the microvessel
density (MVD) in both xenograft types, and a reduction in VEGF
levels in WM239 tumors, no inhibition of tumor growth was seen.
Intrinsic nonresponsiveness to targeted antiangiogenic therapy has
been reported in the clinic [6,55], and based on our findings here,
we propose three non–mutually exclusive mechanisms: bevacizumab-
induced VEGFR2 signaling in cancer cells (discussed above), intracrine
pathways protected from antibody blockade, and down-regulation of
target by tumor microenvironment.
Intracrine VEGF/VEGFR2 signaling that allows cancer cells to
stimulate their own survival pathways without the need for exogenous
secreted factors has been demonstrated for subsets of acute leukemia
cells [21,26,37]. VEGF is also reported to act as an intracrine sur-
vival factor in breast cancer cells through its binding to VEGFR1
[30]. Although growth factors such as VEGF are generally seen as being
operative at the cell surface, there is also evidence that VEGF can be
translocated to the nucleus in some circumstances in endothelial cells
[56]. VEGFR2 can also be internalized and remain in endosomal com-
partments for extended periods where it continues to be phosphorylated
and activate p44/42 MAPK phosphorylation and cell proliferation of
confluent endothelial monolayers [57]. Similar intracellular signaling
presumably occurs in intracrine pathways, where ligand/receptor inter-
actions are completely intracellular [58]. Such internal signaling sys-
tems imply that anti-VEGF neutralizing agents currently used clinically
(such as bevacizumab and aflibercept) may not effectively block those
pathways inside cancer cells. Because cancer cell expression of VEGFRs
is more prevalent than originally thought, this could be a significant
barrier to an effective anticancer therapy with angiogenesis factor–
targeted reagents.
Refractoriness to VEGF signaling blockade in melanoma cells may
also be modulated by the availability of the target protein because of
microenvironmental factors such as hypoxia. It is known that, in
locally advanced solid tumors, oxygen delivery is frequently reduced
or even abolished owing to abnormalities of the tumor vasculature.
Up to 50% to 60% of locally advanced solid tumors may exhibit hyp-
oxic and/or anoxic tissue areas that are heterogeneously distributed
within the tumor mass [59]. Hypoxia plays an important role in regu-
lation of VEGF expression [60,61], and metastatic melanomas contain
hypoxic areas arising in tissue distant from the blood supply [59]. We
found that, in vitro, hypoxia significantly downregulated VEGFR2
expression to almost undetectable levels in metastatic melanoma cells.
This down-regulation may be due to hypoxia-induced overexpression
of VEGF in hypoxic conditions [60], leading to internalization and
degradation of VEGFR2 by melanoma cells. This renders anti-VEGF
therapies, such as bevacizumab, potentially refractory for the areas
of tumors that are hypoxic and may be a reason for mixed success
observed with bevacizumab in clinical trials of malignant mela-
noma to date. Receptor tyrosine kinase small-molecule inhibitors
may be more effective in the treatment of hypoxic cells than mono-
clonal antibodies because of their ability to penetrate cells easier
and thus treat tumors with functional intracellular autocrine VEGF
signaling [25,30,62].
Taken together, our findings demonstrate that both primary and
metastatic melanoma cells may have functional autocrine and intracrine
VEGF/VEGFR2 signaling loops. We also found that bevacizumab is
an effective antiangiogenic but not antitumorigenic agent in hu-
man melanoma xenografted to mice and that it may have undesirable
effects on melanoma cells by increasing the phosphorylation of
VEGFR2. These results suggest that, in the case of cancers with in-
tracrine VEGF/VEGFR2 signaling loops, small-molecule inhibitors
of VEGFR2 may be more effective than neutralizing antibodies at
disease control.
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Table W1. Quantification of Relative VEGFR2 Receptor Expression in Cytosolic and Nuclear Fractions in WM115 and WM239 Melanoma Cells Treated with Bevacizumab (50 μg/ml).
Time (min) pVEGFR2 Site Exogenous VEGF Relative Expression ± SEM
A
Cytosolic fractions 15 Y951 − 0.98 ± 0.24
30 Y951 − 0.86 ± 0.11
15 Y951 + 0.92 ± 0.08
30 Y951 + 0.94 ± 0.16
15 Y1175 − 1.13 ± 0.24
30 Y1175 − 0.87 ± 0.28
15 Y1175 + 1.09 ± 0.18
30 Y1175 + 0.88 ± 0.10
Nuclear fractions 15 Y951 − 0.81 ± 0.07*
30 Y951 − 0.81 ± 0.02*
15 Y951 + 0.92 ± 0.22
30 Y951 + 1.04 ± 0.06
15 Y1175 − 1.00 ± 0.22
30 Y1175 − 0.83 ± 0.11
15 Y1175 + 0.80 ± 0.02*
30 Y1175 + 1.13 ± 0.047
B
Cytosolic fractions 15 Y951 − 0.96 ± 0.08
30 Y951 − 0.88 ± 0.16
15 Y951 + 1.22 ± 0.18
30 Y951 + 1.49 ± 0.60
15 Y1175 − 0.83 ± 0.04*
30 Y1175 − 1.00 ± 0.28
15 Y1175 + 1.14 ± 0.15
30 Y1175 + 1.29 ± 0.17
Nuclear fractions 15 Y951 − 0.97 ± 0.13
30 Y951 − 1.00 ± 0.07
15 Y951 + 1.05 ± 0.13
30 Y951 + 1.27 ± 0.17
15 Y1175 − 0.96 ± 0.08
30 Y1175 − 0.89 ± 0.11
15 Y1175 + 1.14 ± 0.11
30 Y1175 + 1.15 ± 0.13
The relative expression of native and phosphorylated VEGFR2 receptor (at Y951 and Y1175 sites) was assessed at 15- and 30-minute time points after bevacizumab addition, with or without exogenous
VEGF. (A) Addition of bevacizumab had no significant (P > .05) effect on the phosphorylation of VEGFR2 receptor (Y951/Y1175) in cytosolic fractions 15 and 30 minutes after addition (±VEGF),
whereas it significantly (*P < .05) inhibited VEGFR2 phosphorylation at Y951 (both 15 and 30 minutes after addition, −VEGF) and Y1175 (15 minutes after addition, +VEGF) in nuclear fractions in
WM115 cells (*P < .05). (B) Similarly, addition of bevacizumab to the medium of WM239 cells only had a significant inhibitory effect on the phosphorylation of VEGFR2 at Y1175 in cytosolic
fractions after 15 minutes (−VEGF; *P < .05). No significant change in phosphorylation of VEGFR2 (Y951/Y1175) was observed in nuclear fractions 15 and 30 minutes after bevacizumab addition
(±VEGF; P > .05).
